Related references
Note: Only part of the references are listed.Second primary cancers in non-Hodgkin lymphoma: Family history and survival
Subhayan Chattopadhyay et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
The relative risk of second primary cancers in Switzerland: a population-based retrospective cohort study
Anita Feller et al.
BMC CANCER (2020)
Risks for noncutaneous second primary malignancy in cutaneous malignant melanoma survivors: an analysis of data from the Surveillance, Epidemiology, and End Results (SEER) program
Paras P. Vakharia et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)
Overall survival and second primary malignancies in men with metastatic prostate cancer
Juha Mehtala et al.
PLOS ONE (2020)
Risk of Second Primary Cancers Among Long-Term Survivors of Breast Cancer
Dan Li et al.
FRONTIERS IN ONCOLOGY (2020)
Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer
P. Heudel et al.
ANNALS OF ONCOLOGY (2020)
Cautious optimism-the current role of immunotherapy in gastrointestinal cancers
S. Mendis et al.
CURRENT ONCOLOGY (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immune evasion before tumour invasion in early lung squamous carcinogenesis
Celine Mascaux et al.
NATURE (2019)
The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review
Qing-Qing Chai et al.
FRONTIERS IN PHARMACOLOGY (2019)
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Jonathan J. Havel et al.
NATURE REVIEWS CANCER (2019)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Immunological and classical subtypes of oral premalignant lesions
Jean-Philippe Foy et al.
ONCOIMMUNOLOGY (2018)
Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis
Cheng Xu et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials
Dennis A. Eichenauer et al.
HAEMATOLOGICA (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials
Dennis A. Eichenauer et al.
HAEMATOLOGICA (2017)
Precancer Atlas to Drive Precision Prevention Trials
Avrum Spira et al.
CANCER RESEARCH (2017)
The ConSoRe project supports the implementation of big data in oncology
Pierre Heudel et al.
BULLETIN DU CANCER (2016)
Leveraging premalignant biology for immune-based cancer prevention
Avrum Spira et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma
Michael Schaapveld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Milestones of Lynch syndrome: 1895-2015
Henry T. Lynch et al.
NATURE REVIEWS CANCER (2015)
Current knowledge and future research directions in treatment-related second primary malignancies
Lindsay M. Morton et al.
EJC SUPPLEMENTS (2014)
Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors
Lois B. Travis et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Risk Factors Associated With Secondary Sarcomas in Childhood Cancer Survivors: A Report From the Childhood Cancer Survivor Study
Tara O. Henderson et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2012)
Assessing the risk of second malignancies after modern radiotherapy
Wayne D. Newhauser et al.
NATURE REVIEWS CANCER (2011)
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer
Kerryn W. Reding et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Second cancers in survivors of childhood cancer
S Bhatia et al.
NATURE REVIEWS CANCER (2002)
Share Paper
